Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03712293
Recruitment Status : Recruiting
First Posted : October 19, 2018
Last Update Posted : October 19, 2018
Sponsor:
Information provided by (Responsible Party):
InSightec

Brief Summary:
The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2.0 used as a tool to disrupt the BBB in patients with Glioblastoma undergoing standard of care therapy.

Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme Device: BBB Disruption with Chemotherapy Arm Not Applicable

Detailed Description:
This is a prospective, multisingle-center, single-arm study to establish the safety and feasibility of BBB disruption along the periphery of tumor resection cavity using the ExAblate Neuro Model 4000 Type 2.0 (220 kHz) system. For this study, patients will be eligible to enroll in the study prior to beginning the planned adjuvant TMZ chemotherapy phase of treatment. Of note, only patients who are deemed eligible for adjuvant TMZ will be eligible for enrollment. This study will enroll up to 20 subjects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Intervention Model Description: This study will enroll up to 10 patients who are eligible and recommended for the standard adjuvant phase of TMZ chemotherapy. The goal is for all subjects to undergo ExAblate Type 2.0 BBB disruption procedures on one of the first three days of each TMZ dosing cycle throughout the adjuvant phase (up to 6 cycles).
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier Disruption for the Treatment of Glioblastoma in Patients Undergoing Standard Chemotherapy
Actual Study Start Date : August 28, 2018
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BBB Disruption with Chemotherapy Arm
All subjects in this arm will undergo ExAblate Type 2.0 BBBD procedures on one of the first three days of each TMZ dosing cycle throughout the adjuvant phase (up to 6 cycles).
Device: BBB Disruption with Chemotherapy Arm
The ExAblate BBB disruption of targets associated with enhancing post-resection MRI imaging procedure will be performed with ExAblate 4000 type 2.0 system and will coincide with on one of three first days of each planned TMZ adjuvant therapy cycle as one procedure per cycle.




Primary Outcome Measures :
  1. Adverse Events Safety Profile [ Time Frame: 7 months ]
    The type and severity of adverse events post-procedure will be assessed for overall safety. Safety of the BBBD procedure will be evaluated through patient examination and MRI assessments during the treatment and by their standard of care follow-up MRI scans and clinical visits. The standard of care follow-up MRI scans will be used to continue safety monitoring post-BBBD procedures and after adjuvant TMZ chemotherapy is completed.


Secondary Outcome Measures :
  1. Blood Brain Barrier Opening [ Time Frame: 7 months ]
    The ability to open the Blood Brain Barrier with ExAblate Focused Ultrasound will be evaluated by contrast MR imaging. If the procedure was successful, the area treated with show contrast enhancement on MRI.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patient is eligible for adjuvant TMZ treatment based on the current standard of care.
  2. Men or women.
  3. Age between 19 and 80 years, inclusive.
  4. Able and willing to give informed consent.
  5. Grade IV glioma (GBM) confirmed through assessment of surgical specimens by a board-certified neuropathologist.
  6. Combined radiation/TMZ treatment is completed based on the prescribed standard of care regimen.
  7. Karnofsky rating 70-100 (See Appendix B).
  8. Able to communicate during the ExAblate BBBD procedure.
  9. Able to attend all study visits (i.e., life expectancy of at least 3 months).

Exclusion Criteria:

  1. The sonication pathway to the tumor involves:

    i. More than 30% of the skull area traversed by the sonication pathway is covered by scars, scalp disorders (e.g., eczema), or atrophy of the scalp.

    ii. Clips or other metallic implanted objects in the skull or the brain, except shunts.

  2. The subject presents with symptoms and signs of increased intracranial pressure (e.g., headache, nausea, vomiting, lethargy, and papilledema).
  3. Patients with cerebellar or brainstem tumors.
  4. Patient receiving bevacizumab (Avastin) therapy.
  5. Patients receiving treatment with corticosteroid doses greater than dexamethasone 16mg daily (or equivalent).
  6. Patients undergoing other concurrent therapies such as chemotherapy wafers, immunotoxins delivered by convection-enhanced delivery, regionally administered gene and viral therapies, immunotherapies, focal irradiation with brachytherapy, stereotactic radiosurgery, laser interstitial thermotherapy, and tumor treatment fields therapy. These regimens have been shown to cause contrast enhancement in the resection cavity boundary, which can be difficult to differentiate from true tumor recurrence [35] [36], [37-39].
  7. Cardiac disease or unstable hemodynamics including:

    i. Documented myocardial infarction within six months of enrollment. ii. Unstable angina on medication. iii. Congestive heart failure. iv. Left ventricular ejection fraction <50%. v. History of a hemodynamically unstable cardiac arrhythmia. vi. Cardiac pacemaker.

  8. Severe hypertension (diastolic BP > 100 on medication).
  9. Anti-coagulant therapy, or medications known to increase risk of hemorrhage within washout period prior to treatment (i.e., antiplatelet or vitamin K inhibitor anticoagulants within 7 days, non-vitamin K inhibitor anticoagulants within 72 hours, or heparin-derived compounds within 48 hours of treatment).
  10. History of a bleeding disorder, coagulopathy or with a history of spontaneous tumor hemorrhage.
  11. Cerebral or systemic vasculopathy.
  12. Evidence of new focal neurological deficits including, but not limited to, motor weakness or speech impairment within 7-14 days prior to the first BBBD procedure.
  13. History of drug or alcohol use disorder.
  14. Active seizure disorder or epilepsy (seizures despite medical treatment).
  15. Known sensitivity to gadolinium-based contrast agents.
  16. Known sensitivity to DEFINITY® ultrasound contrast agent or perflutren.
  17. Contraindications to MRI such as non-MRI-compatible implanted devices.
  18. Large subjects not fitting comfortably into the MRI scanner.
  19. Difficulty lying supine and still for up to 4 hours in the MRI unit or claustrophobia.
  20. Positive pregnancy test (women of childbearing potential).
  21. Severely impaired renal function with estimated glomerular filtration rate <30 mL/min/1.73m2 and/or on dialysis.
  22. Right to left or bi-directional cardiac shunt.
  23. Subjects with evidence of cranial or systemic infection.
  24. Subjects with a family or personal history of QT prolongation or taking concomitant medications known to cause QTc prolongation, or QT prolongation observed on screening ECG (QTc > 450 for men and >470 for women).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03712293


Contacts
Layout table for location contacts
Contact: Martin Bernstein +97248131313 ext 628 mbrnstn@gmail.com
Contact: Kathy L McDermott +12146302000

Locations
Layout table for location information
Korea, Republic of
Severance Hospital, Yonsei University Health System Recruiting
Seoul, Seodaemun-gu, Korea, Republic of, 03722
Contact: Eunjung Kweon, RN    +82-2-2224-4578    KWEONEJ@yuhs.ac   
Contact: Jiseon Oh    +82-2-2228-0478    WLTJS1828@yuhs.ac   
Principal Investigator: JinWoo Chang, MD, PhD         
Sub-Investigator: Jong Hee Chang, MD, PhD         
Sub-Investigator: Hyun Ho Jung, MD, PhD         
Sub-Investigator: Na Young Jung, MD, PhD         
Sub-Investigator: Il Jang, MD, PhD         
Sponsors and Collaborators
InSightec
Investigators
Layout table for investigator information
Study Director: Martin Bernstein InSightec

Layout table for additonal information
Responsible Party: InSightec
ClinicalTrials.gov Identifier: NCT03712293     History of Changes
Other Study ID Numbers: BT008K
First Posted: October 19, 2018    Key Record Dates
Last Update Posted: October 19, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue